3 ^rd International Conference on Cannabis and Medicinal Research July 15-16,2019 Bangkok, Thailand

Biography:

Tajudeen O. Jimoh is a Guest Doctoral Student at the Natural Products with Antiparasite and Antimicrobial Activity (YaBiNapa) Yaounde-Bielefeld Graduate School, Thailand

Abstract:

INTRODUCTION: Recent studies on the beneficial health effects of plants have raised the interest of researchers on the possible preventive and protective actions of plant peptides against endoparasites. However, parasitic infections are on the increase in sub-Sahara Africa and its complications are directly proportional to the mortality rate and reduced productivity. It is worthy of note that the protozoa, nematodes, trematodes, and cestodes, which affect more than 30% of the human population pose high level of risk to the world. Moreover, the limitation of the existing vaccinations due to parasite resistant coupled with the expensive cost of available synthetic therapeutics drugs have necessitated the need to search for more potent and cheap plant-based alternatives anti-parasitic drugs. Moringa oleifera (Family: Moringaceae) is a tropical plant with scanty information on the possible mechanism by which it elicits its anti-parasitic properties. CONLUSION: Essentially, aminopeptidases have been proposed as being responsible for releasing single amino acids from proteins; or peptides and there have been divergent views on where this takes place and which enzymes are responsible. It is probable that when plasmodium falciparum enzyme is inhibited it blocked hemoglobin degradation which starves the parasite to death. Therefore, this study is investigating peptides from Moringa oleifera leaves with possible inhibitory properties against plasmodium falciparum. To this end, this approach may provide fundamental mechanism for the characterization of novel bioactive compound from plant origin for the management of malaria.

Biography:

Although diagnosis techniques and treatment methods of cancer have been developed and nursing approaches fully examined from various viewpoints, few of these accomplishments are applicable to physical assessment of schizophrenic patients with stomach cancer. In this study, which was conducted after being approved by the IRB of Iwaki Meisei University, basic information on the content of physical assessment of schizophrenic patients with stomach cancer by nurses at psychiatric hospitals was gathered and organized.

Results

128 nurses (respondence rate 85.3%) including 61 males and 67 females 70% of who were 40 years or older responded the questionnaire. 77 nurses had experience working at general hospitals, and 51 nurses had been working only at psychiatric hospitals. Physical assessment by nurses included “poor appetite” (82), “weight loss” (80), “bloody stool” (74), “general fatigue” (68), and “edema” (16) (multiple answers included). The knowledge and techniques that the nurses wanted to acquire included “monitor management” (86), “NGT management” (71), “abdominal symptoms” (46), and “cancer pain” (34) (multiple answers included).

Discussion

The longer nurses work at psychiatric hospitals, the more they seem to lose interest in physical assessment of symptoms caused by cancer. The importance of developing an education program focusing on how to assess cancer pains in patients for whom narcotic drugs are not used was recognized and suggested.

Abstract:

Harumi ARAI received a doctoral degree in health and welfare science from the graduate school of Takasaki University of Health and Welfare. She is a professor in psychiatric nursing and has been conducting field research for over 15 years on palliative care provided and needed for long-stay schizophrenic patients with cancer at psychiatric hospitals.

Biography:

Kenzi Riboulet-Zemouli is a French-Algerian multidisciplinary researcher and advocate for sustainable drug policy reforms. He is head of the Drug Policies & Human Rights program of the European Institute for Multidisciplinary Studies on Human Rights and Science (Knowmad Institut), as well as co-founder of the think-tank FAAAT. Focused on Action-research as a catalyzer for legal and social changes, Kenzi has been particularly involved in studying alternative pathways for Cannabis policy reform, linking international law with local initiatives. His work articulates around the ethics, evidence-base, human rights aspects, fair trade components, and criteria of sustainability of legally-regulated use, production, and markets of internationally controlled and/or psychoactive plants, fungi, products or substances.

Abstract:

The World Health Organization (WHO) is the leading standardization entity and public health referent globally. Beside this role, WHO is also directly mandated by the International Drug Control Conventions (IDCC) as the provider of official scientific and independent assessments of drugs for the purpose of scheduling (i.e., determining the extent of use-related harms and the scope of therapeutic properties of psychoactive plants, fungi, products or substances in order to categorize and hierarchically list them) within the IDCC. Different sorts and categories of products and substances derived from the Cannabis sativa L. plant are currently scheduled within the IDCC, although having never been assessed by the WHO or the international organizations with similar mandate preceding the WHO before the 2nd World War. For this reason, the WHO has been undertaking since 2016 a process of review and assessment of these Cannabis-related products and substances, recommending important changes in their level and status of scheduling within the IDCC. We comprehensively followed the WHO assessment processes and reviewed the contents submitted to its Experts in charge of the assessment at all stages. We analysed the outcome, and estimated the impacts and consequences of the changes in IDCC scheduling status of Cannabis-related products and substances for the medical and research fields. Our results show that the new official position of the WHO conveyed by the outcome of its Experts acknowledges that Cannabis is legitimate in medicine, consider herbal Cannabis less dangerous than other substances placed in Schedule I of the 1961 Convention, encourage governments to provide access to a variety of formulations while leaving them a wide discretion in the choice of products to regulate, and flexibility of policies to implement. Our research concluded to a clarified international policy landscape that calls for the involvement of other international tools, such as the frameworks developed by WHO for the safe and regulated use of herbal and phytomedicines and their pharmacovigilance.

Biography:

Dr. Dani Gordon is one of the world leaders in Clinical Cannabis Medicine, having treated thousands of patients with medical cannabis and cannabinoid medicines in Canada, and now in charge of training the first physicians in the UK & Europe in cannabis medicine for clinical use and now speaks internationally on the topic.  She is a top media expert in CBD and cannabis, having been featured on numerous TV and print media outlets including: the BBC, Telegraph, Channel 4, Glamour Magazine, Fast Company and many more. She now lives in London, UK with her family and also still keeps her cannabinoid medicine practice part time in Canada.

Abstract:

This lecture will provide a unique perspective from a medical doctor training in cannabinoid medicine and having treated thousands of patients with cannabis medicines and who is now in charge of education of UK physicians.   This lecture will focus on clinical uses of cannabis medicines for wide variety of conditions and review the level of evidence for each. The lecture will start by introducing the key medicinal chemical ‘key players’ in the plant and how they work in the brain and body, and how to use each clinically with patients, including possible drug/herb interactions and a review of the different types of cannabis products available.  It will end with a series of clinical case studies from Dr. Gordon’s clinical work with cannabis in a Canadian population including cases on chronic pain, epilepsy, mood disorders, autoimmune disease and cancer.